<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048537</url>
  </required_header>
  <id_info>
    <org_study_id>202010009MIND</org_study_id>
    <nct_id>NCT05048537</nct_id>
  </id_info>
  <brief_title>18F-FACBC PET/CT and the PSA Kinetics for PCa Patients With Biochemical Recurrence.</brief_title>
  <official_title>The Correlation Between the Detection Rate of 18F-FACBC PET/CT and the PSA Kinetics for Prostate Cancer Patients With Biochemical Recurrence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer (PCa) is the fifth-most common cancer for male with a seventh highest&#xD;
      cancer-related death in Taiwan. Currently, the incidence and mortality rate are still&#xD;
      increasing rapidly. The treatment decision planning is made up by clinical charts like&#xD;
      Gleason score (GS), TNM stage and serum prostate-specific antigen (PSA) level. However, after&#xD;
      definitive therapy for PCa with either external beam radiotherapy (EBRT) or radical&#xD;
      prostatectomy (RP), up to half patients experience biochemical recurrence (BCR). Although not&#xD;
      all patients with BCR proceed to develop disease progression, it is important to identify&#xD;
      early lesion to initiate salvage treatment.&#xD;
&#xD;
      Anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (18F-FACBC) positron emission&#xD;
      tomography (PET) is a imaging marker for L-amino acid transport evaluation. Many cancers&#xD;
      including PCa have up-regulated amino acid transport tied to their proliferative potential.&#xD;
      Recently, 18F-FACBC was included in the National Comprehensive Cancer Network (NCCN)&#xD;
      guidelines for the management of recurrent PCa patients. As we know, PSA level and PSA&#xD;
      kinetics are valuable for the prediction of recurrence. The objective of this study is to&#xD;
      investigate the correlation between the detection rate of 18F-FACBC PET/CT and the PSA&#xD;
      kinetics for PCa patients with BCR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The detection rate of 18F-FACBC PET/CT</measure>
    <time_frame>30 minutes</time_frame>
    <description>The correlation between the positive/negative results of 18F-FACBC scans and the PSA kinetics in prostate cancer patients with biochemical recurrence.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Biochemical Relapse Fo Malignant Neoplasm of Prostate</condition>
  <arm_group>
    <arm_group_label>18F-FACBC PET/CT and the PSA kinetics for PCa patients with BCR.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FACBC PET/CT</intervention_name>
    <description>10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins</description>
    <arm_group_label>18F-FACBC PET/CT and the PSA kinetics for PCa patients with BCR.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  PCa patients with BCR&#xD;
&#xD;
          -  Serum PSA data and pathologic report&#xD;
&#xD;
          -  Agreement consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Claustrophobia and unstable vital signs&#xD;
&#xD;
          -  Disagreement&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>prostate cancer patients with biochemical recurrence</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Hsien Chou, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Hsien Chou, MD</last_name>
    <phone>+886-97252572</phone>
    <email>Y06922@ms1.ylh.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Hsien Chou, MD</last_name>
      <phone>097252572</phone>
      <email>Y06922@ms1.ylh.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>18F-FACBC</keyword>
  <keyword>Biochemical recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

